These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
535 related articles for article (PubMed ID: 34616756)
1. When Origin Matters: Properties of Mesenchymal Stromal Cells From Different Sources for Clinical Translation in Kidney Disease. Calcat-I-Cervera S; Sanz-Nogués C; O'Brien T Front Med (Lausanne); 2021; 8():728496. PubMed ID: 34616756 [TBL] [Abstract][Full Text] [Related]
2. Harmonised culture procedures minimise but do not eliminate mesenchymal stromal cell donor and tissue variability in a decentralised multicentre manufacturing approach. Calcat-I-Cervera S; Rendra E; Scaccia E; Amadeo F; Hanson V; Wilm B; Murray P; O'Brien T; Taylor A; Bieback K Stem Cell Res Ther; 2023 May; 14(1):120. PubMed ID: 37143116 [TBL] [Abstract][Full Text] [Related]
3. Systematic review and meta-analysis of cell therapy for COVID-19: global clinical trial landscape, published safety/efficacy outcomes, cell product manufacturing and clinical delivery. Couto PS; Al-Arawe N; Filgueiras IS; Fonseca DLM; Hinterseher I; Catar RA; Chinnadurai R; Bersenev A; Cabral-Marques O; Moll G; Verter F Front Immunol; 2023; 14():1200180. PubMed ID: 37415976 [TBL] [Abstract][Full Text] [Related]
4. Upstream Process Protocol for MSCs Isolated from Different Human-Based Tissue Origins. Kılıç P; Özdemir C; Coşar B; Savran BN; Sarıkaya A; Sargon B; Toprakkale A; Songür İ; Kandemir Seçgin Ö; Akpınar Oktar P; Çetindağ EN; Yurtsever Sarıca D; Taşdelen S; Ezer Ü; Kürekçi AE; Gürman G Methods Mol Biol; 2024 Jul; ():. PubMed ID: 38967911 [TBL] [Abstract][Full Text] [Related]
5. Translation of a standardized manufacturing protocol for mesenchymal stromal cells: A systematic comparison of validation and manufacturing data. Rojewski MT; Lotfi R; Gjerde C; Mustafa K; Veronesi E; Ahmed AB; Wiesneth M; Körper S; Sensebé L; Layrolle P; Hellem S; Schrezenmeier H Cytotherapy; 2019 Apr; 21(4):468-482. PubMed ID: 30926359 [TBL] [Abstract][Full Text] [Related]
6. Optimization of Mesenchymal Stromal Cell (MSC) Manufacturing Processes for a Better Therapeutic Outcome. Fernández-Santos ME; Garcia-Arranz M; Andreu EJ; García-Hernández AM; López-Parra M; Villarón E; Sepúlveda P; Fernández-Avilés F; García-Olmo D; Prosper F; Sánchez-Guijo F; Moraleda JM; Zapata AG Front Immunol; 2022; 13():918565. PubMed ID: 35812460 [TBL] [Abstract][Full Text] [Related]
7. Processing and Ex Vivo Expansion of Adipose Tissue-Derived Mesenchymal Stem/Stromal Cells for the Development of an Advanced Therapy Medicinal Product for use in Humans. Labedz-Maslowska A; Szkaradek A; Mierzwinski T; Madeja Z; Zuba-Surma E Cells; 2021 Jul; 10(8):. PubMed ID: 34440677 [TBL] [Abstract][Full Text] [Related]
8. Strategies to enhance immunomodulatory properties and reduce heterogeneity in mesenchymal stromal cells during ex vivo expansion. Srinivasan A; Sathiyanathan P; Yin L; Liu TM; Lam A; Ravikumar M; Smith RAA; Loh HP; Zhang Y; Ling L; Ng SK; Yang YS; Lezhava A; Hui J; Oh S; Cool SM Cytotherapy; 2022 May; 24(5):456-472. PubMed ID: 35227601 [TBL] [Abstract][Full Text] [Related]
9. Deterministic and stochastic approaches in the clinical application of mesenchymal stromal cells (MSCs). Pacini S Front Cell Dev Biol; 2014; 2():50. PubMed ID: 25364757 [TBL] [Abstract][Full Text] [Related]
10. Off-the-Shelf Cord-Blood Mesenchymal Stromal Cells: Production, Quality Control, and Clinical Use. Montemurro T; Lavazza C; Montelatici E; Budelli S; La Rosa S; Barilani M; Mei C; Manzini P; Ratti I; Cimoni S; Brasca M; Prati D; Saporiti G; Astori G; Elice F; Giordano R; Lazzari L Cells; 2024 Jun; 13(12):. PubMed ID: 38920694 [TBL] [Abstract][Full Text] [Related]
11. Study on the Umbilical Cord-Mesenchymal Stem Cell Manufacturing Using Clinical-Grade Culture Medium. Kurogi H; Takijiri T; Sakumoto M; Isogai M; Takahashi A; Okubo T; Koike T; Yamada T; Nagamura-Inoue T; Sakaki-Yumoto M Tissue Eng Part C Methods; 2022 Jan; 28(1):23-33. PubMed ID: 35018815 [TBL] [Abstract][Full Text] [Related]
12. Soliciting strategies for developing cell-based reference materials to advance mesenchymal stromal cell research and clinical translation. Viswanathan S; Keating A; Deans R; Hematti P; Prockop D; Stroncek DF; Stacey G; Weiss DJ; Mason C; Rao MS Stem Cells Dev; 2014 Jun; 23(11):1157-67. PubMed ID: 24422625 [TBL] [Abstract][Full Text] [Related]
13. Ex vivo-expanded highly pure ABCB5 Kerstan A; Niebergall-Roth E; Esterlechner J; Schröder HM; Gasser M; Waaga-Gasser AM; Goebeler M; Rak K; Schrüfer P; Endres S; Hagenbusch P; Kraft K; Dieter K; Ballikaya S; Stemler N; Sadeghi S; Tappenbeck N; Murphy GF; Orgill DP; Frank NY; Ganss C; Scharffetter-Kochanek K; Frank MH; Kluth MA Cytotherapy; 2021 Feb; 23(2):165-175. PubMed ID: 33011075 [TBL] [Abstract][Full Text] [Related]
14. Use of priming strategies to advance the clinical application of mesenchymal stromal/stem cell-based therapy. Miceli V World J Stem Cells; 2024 Jan; 16(1):7-18. PubMed ID: 38292438 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of GMP-compliant culture media for in vitro expansion of human bone marrow mesenchymal stromal cells. Wuchter P; Vetter M; Saffrich R; Diehlmann A; Bieback K; Ho AD; Horn P Exp Hematol; 2016 Jun; 44(6):508-18. PubMed ID: 26911671 [TBL] [Abstract][Full Text] [Related]
16. Pancreas-derived mesenchymal stromal cells share immune response-modulating and angiogenic potential with bone marrow mesenchymal stromal cells and can be grown to therapeutic scale under Good Manufacturing Practice conditions. Thirlwell KL; Colligan D; Mountford JC; Samuel K; Bailey L; Cuesta-Gomez N; Hewit KD; Kelly CJ; West CC; McGowan NWA; Casey JJ; Graham GJ; Turner ML; Forbes S; Campbell JDM Cytotherapy; 2020 Dec; 22(12):762-771. PubMed ID: 32828673 [TBL] [Abstract][Full Text] [Related]
17. Inactivated Platelet Lysate Supports the Proliferation and Immunomodulant Characteristics of Mesenchymal Stromal Cells in GMP Culture Conditions. Mareschi K; Castiglia S; Adamini A; Rustichelli D; Marini E; Banche Niclot AGS; Bergallo M; Labanca L; Ferrero I; Fagioli F Biomedicines; 2020 Jul; 8(7):. PubMed ID: 32708843 [TBL] [Abstract][Full Text] [Related]
18. Standardization of Good Manufacturing Practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications. Wuchter P; Bieback K; Schrezenmeier H; Bornhäuser M; Müller LP; Bönig H; Wagner W; Meisel R; Pavel P; Tonn T; Lang P; Müller I; Renner M; Malcherek G; Saffrich R; Buss EC; Horn P; Rojewski M; Schmitt A; Ho AD; Sanzenbacher R; Schmitt M Cytotherapy; 2015 Feb; 17(2):128-39. PubMed ID: 24856898 [TBL] [Abstract][Full Text] [Related]
19. Development of a human umbilical cord-derived mesenchymal stromal cell-based advanced therapy medicinal product to treat immune and/or inflammatory diseases. Mebarki M; Iglicki N; Marigny C; Abadie C; Nicolet C; Churlaud G; Maheux C; Boucher H; Monsel A; Menasché P; Larghero J; Faivre L; Cras A Stem Cell Res Ther; 2021 Nov; 12(1):571. PubMed ID: 34774107 [TBL] [Abstract][Full Text] [Related]
20. Strategies to address mesenchymal stem/stromal cell heterogeneity in immunomodulatory profiles to improve cell-based therapies. Dunn CM; Kameishi S; Grainger DW; Okano T Acta Biomater; 2021 Oct; 133():114-125. PubMed ID: 33857693 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]